A highly reactive immune system excels at fighting viruses but becomes more likely to attack itself
For generations, medicine treated the immune system as a single, universal architecture — but a landmark study from the Garvan Institute and UNSW Sydney reveals that women and men are, at the genetic level, running fundamentally different immune operating systems. Analyzing over 1.25 million individual immune cells from nearly 1,000 people, researchers identified more than 1,000 genetic switches — scattered not on sex chromosomes but throughout the entire genome — that behave differently depending on sex. The same biological vigilance that equips women's immune systems to fight viral threats more aggressively also makes them nine times more likely than men to develop lupus, a disparity that has long been observed but never so precisely explained. The findings call medicine toward a more honest reckoning: that treating disease without accounting for sex is not neutrality, but a form of blindness.
- Women develop lupus at nine times the rate of men, a staggering disparity that has persisted without a clear genetic explanation — until now.
- Over 1,000 genetic switches operating differently in female and male immune cells were identified, and crucially, most sit on shared chromosomes rather than the sex chromosomes scientists had long suspected.
- Women's immune cells are primed for inflammatory response — better at fighting viruses, but far more prone to turning that firepower against the body's own tissues.
- Current autoimmune treatments use broad immunosuppressants that ignore these sex-based differences entirely, potentially limiting their effectiveness for millions of women.
- Researchers are now pointing toward precision medicine that accounts for a patient's baseline immune genetics, offering hope that lupus and similar conditions could finally be treated on their own biological terms.
Women are nine times more likely than men to develop lupus — and researchers at the Garvan Institute and UNSW Sydney have now mapped the genetic reasons why. In the most detailed cellular study of immune sex differences ever conducted, the team sequenced more than 1.25 million individual immune cells from nearly 1,000 healthy people, uncovering over 1,000 genetic switches that operate differently in female and male immune systems.
The finding that surprised researchers most was where those switches live. Rather than residing on the X and Y sex chromosomes, the vast majority are scattered across the autosomes — the chromosomes both sexes share — suggesting that sex-based immune differences are embedded throughout the entire genome.
The cellular picture that emerges is one of trade-offs. Women carry higher proportions of B cells and regulatory T cells, whose genetic activity is oriented toward inflammatory pathways — the body's alarm system. Men carry more monocytes focused on basic cellular maintenance. Women's more reactive immune systems excel at neutralizing viruses early, but that same hypervigilance makes the immune system more likely to misidentify the body's own tissues as threats. Men, with their less inflammatory baseline, face greater susceptibility to infections and certain cancers instead.
First author Dr. Seyhan Yazar argues the findings demand a fundamental shift in how medicine is practiced, noting that studies still routinely overlook sex differences in immunity, biasing both research and treatment. The team also identified specific genetic variants in two lupus-linked genes that show female-biased expression, providing a direct biological explanation for the disease's unequal burden.
The broader implication is a move away from the sledgehammer of broad immunosuppressants toward precision therapies calibrated to how a patient's immune system actually works at a genetic baseline — a shift that could meaningfully change outcomes for the millions of women living with autoimmune disease.
Women are nine times more likely than men to develop lupus, and researchers at the Garvan Institute of Medical Research and UNSW Sydney have now identified why: over 1,000 genetic switches scattered across the human genome operate differently in female and male immune cells, tilting women's immune systems toward a state of perpetual vigilance that protects against viral infection but leaves them vulnerable to autoimmune attack.
The discovery, published in The American Journal of Human Genetics and timed to World Lupus Day on May 10, emerges from the most detailed cellular examination of sex differences in immunity ever conducted. Researchers sequenced more than 1.25 million individual immune cells drawn from nearly 1,000 healthy people, a scale of precision that was impossible just years ago. What they found upends a long-held assumption: the genetic switches driving these differences are not primarily located on the X and Y sex chromosomes, as many had expected. Instead, the vast majority sit on the autosomes—the chromosomes shared by both sexes—suggesting that sex-based immune differences are woven into the fabric of our entire genome, not confined to the sex chromosomes themselves.
The cellular profiles tell a striking story. Women's immune systems are stocked with higher proportions of B cells and regulatory T cells, immune soldiers whose genetic activity is heavily oriented toward inflammatory pathways—the body's alarm system for detecting and fighting threats. Men, by contrast, carry more monocytes, the first responders that focus their genetic machinery on basic cellular maintenance and protein production. This difference is not incidental. A highly reactive immune system, constantly primed for action, excels at neutralizing viruses before they take hold. But that same hypervigilance carries a cost: the immune system becomes more likely to misidentify the body's own tissues as invaders and attack them, the hallmark of autoimmune disease. Men pay a different price for their less inflammatory baseline—they are generally more susceptible to infections and non-reproductive cancers.
Dr. Seyhan Yazar, the study's first author, emphasizes that this finding demands a reckoning with how medicine has historically been practiced. "Our findings show that the immune system needs to be studied with sex in mind," he says. "Even though we know men's and women's immune systems differ, many studies still overlook these differences, which can limit how well we understand disease, and in turn bias treatment options." The research was made possible by advances in single-cell sequencing technology, which can now examine individual immune cells rather than averaging across millions at once—a crucial distinction that allowed researchers to spot genetic variations that bulk blood analysis would have missed entirely.
The implications for treatment are profound. Current autoimmune therapies typically take a sledgehammer approach, using broad immunosuppressants that dampen the entire immune system. But if women's and men's autoimmune diseases arise from fundamentally different genetic architectures, then treating them identically may be futile. The researchers identified specific genetic variants affecting two genes linked to systemic lupus erythematosus that show female-biased expression, offering a biological explanation for why lupus strikes women so much more frequently. Dr. Sara Ballouz, a co-senior author, notes that "female-biased genes are heavily enriched in inflammatory pathways, we now have another biological rationale for why the immune system can more easily mistakenly attack the body's own tissues in women."
The path forward points toward precision medicine tailored not just to disease type but to the patient's baseline immune genetics. As Professor Joseph Powell, director of Garvan's Translational Genomics Program, puts it: "Treatments need to be tailored not just to the disease, but to how a patient's immune system operates at a baseline genetic level." For the millions of women living with lupus and other autoimmune conditions, this research suggests that one-size-fits-all management may finally give way to therapies designed around the specific biological realities of how their immune systems actually work.
Citas Notables
The immune system needs to be studied with sex in mind. Many studies still overlook these differences, which can limit how well we understand disease and bias treatment options.— Dr. Seyhan Yazar, Garvan Institute
Treatments need to be tailored not just to the disease, but to how a patient's immune system operates at a baseline genetic level.— Professor Joseph Powell, Garvan Institute
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that these genetic switches are on the autosomes rather than the sex chromosomes?
Because it tells us something fundamental about how sex differences in immunity are encoded. If it were just about X and Y, we'd have a simpler story. Instead, the fact that most of these switches are scattered across shared chromosomes means that sex-based immune differences are baked into the genome at a much deeper level than we thought. It's not a separate system—it's woven throughout.
So women's immune systems are essentially more aggressive?
Not aggressive exactly—more reactive. There's a trade-off built in. That reactivity is why women tend to fight off viral infections better. But the same machinery that catches a virus quickly can also misfire and attack your own cells. It's like having a smoke detector that's extremely sensitive. Great for catching real fires, but it goes off when you're just cooking dinner.
Does this mean autoimmune disease is inevitable for women?
No. Genetics load the gun, but they don't pull the trigger. Hormones, environment, infections, stress—all of those matter too. What this research does is explain why women start from a different biological baseline. It's not about destiny; it's about understanding the terrain you're working with.
How does this change treatment?
Right now, doctors use the same immunosuppressant drugs for men and women with the same diagnosis. But if the underlying genetic drivers are different, why would the same drug work equally well for both? The research suggests we need to move toward therapies that target the specific pathways that are actually overactive in each patient, rather than just turning down the whole immune system.
Is this research already being used in clinics?
Not yet. This is foundational science. It explains the why. Now researchers need to use these insights to design new drugs and test whether targeting these specific pathways actually works better than current treatments. That's the next phase.